Inventor · disambiguated record
Todd Kinsella
Also filed as: KINSELLA TODD · KINSELLA TODD M
47 granted patents·19 pending applications·218 citations·filing 1995–2022
97Inventor score
Files withRIGEL PHARMACEUTICALS INC46KINSELLA TODD M5VIVIDION THERAPEUTICS INC3LORENS JAMES B2BHAMIDIPATI SOMASEKHAR1
Top patents by PatentIndex Score
66 records- 0191US7105341B2In vivo production of cyclic peptidesRIGEL PHARMACEUTICALS INC·Filed 2001·Granted Sep 12, 2006·22 cites·7 claims
- 0290US9878992B2GDF-8 inhibitorsRIGEL PHARMACEUTICALS INC·Filed 2017·Granted Jan 30, 2018·6 cites·2 claims
- 0390US9145433B2GDF-8 inhibitorsBHAMIDIPATI SOMASEKHAR·Filed 2013·Granted Sep 29, 2015·13 cites·21 claims
- 0489US10822337B2TGF-β inhibitorCRIGEL PHARMACEUTICALS INC·Filed 2016·Granted Nov 3, 2020·4 cites·16 claims
- 0589US7566685B2Methods and compositions for screening using diphtheria toxin constructsRIGEL PHARMACAUTICALS INC·Filed 2006·Granted Jul 28, 2009·15 cites·10 claims
- 0688US7252952B2In vivo production of cyclic peptides for inhibiting protein—protein interactionRIGEL PHARMACEUTICALS INC·Filed 2003·Granted Aug 7, 2007·19 cites·10 claims
- 0788US5830725ARapid, stable high-titre production of recombing retrovirusTRUSTEES FOR THE LELAND STANFO·Filed 1995·Granted Nov 3, 1998·91 cites·23 claims
- 0887US7378248B2In vivo production of cyclic peptides for inhibiting protein-protein interactionRIGEL PHARMACEUTICALS INC·Filed 2005·Granted May 27, 2008·7 cites·5 claims
- 0985US7208571B2In vivo production of cyclic peptidesRIGEL PHARMACEUTICALS INC·Filed 2004·Granted Apr 24, 2007·8 cites·8 claims
- 1082US9040462B2In vivo production of cyclic peptides for inhibiting protein-protein interactionLORENS JAMES B·Filed 2008·Granted May 26, 2015·5 cites·18 claims
- 1180US7566765B2Heterocyclic compounds containing a nine-membered carbon-nitrogen ringRIGEL PHARMACEUTICALS INC·Filed 2005·Granted Jul 28, 2009·4 cites·4 claims
- 1280US7425418B2Compounds that modulate processes associated with IgE productionRIGEL PHARMACEUTICALS INC·Filed 2002·Granted Sep 16, 2008·3 cites·20 claims
- 1378US10759855B2Antigen binding molecules to TIGITRIGEL PHARMACEUTICALS INC·Filed 2017·Granted Sep 1, 2020·1 cites·9 claims
- 1478US9884868B2TGF-beta inhibitorsRIGEL PHARMACEUTICALS INC·Filed 2016·Granted Feb 6, 2018·2 cites·36 claims
- 1577US12227508B2TGF-β inhibitorsRIGEL PHARMACEUTICALS INC·Filed 2022·Granted Feb 18, 2025·0 cites·22 claims
- 1677US10781239B2In vivo engineered cereblon proteinVIVIDION THERAPEUTICS INC·Filed 2019·Granted Sep 22, 2020·1 cites·24 claims
- 1777US7056687B2Methods and compositions for screening for altered cellular phenotypesRIGEL PHARMACEUTICALS INC·Filed 2002·Granted Jun 6, 2006·4 cites·59 claims
- 1875US7060433B1Methods and compositions for screening using diphtheria toxin constructsRIGEL PHARMACEUTICALS INC·Filed 2000·Granted Jun 13, 2006·2 cites·29 claims
- 1969US11466018B2TGF-β inhibitorsRIGEL PHARMACEUTICALS INC·Filed 2020·Granted Oct 11, 2022·0 cites·16 claims
- 2068US8796254B2Methods for using carboxamide, sulfonamide and amine compoundsPAYAN DONALD·Filed 2011·Granted Aug 5, 2014·2 cites·21 claims
- 2168US7563585B2Methods of assaying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a thioredoxin-like 32 kDa protein (TXNL)RIGEL PHARMACEUTICALS INC·Filed 2006·Granted Jul 21, 2009·0 cites·11 claims
- 2267US6979549B2Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a CLLD8 proteinRIGEL PHARMACEUTICALS INC·Filed 2002·Granted Dec 27, 2005·5 cites·52 claims
- 2367US2008003620A1Methods of identifying compounds that modulate il-4 receptor-mediated ige synthesis utilizing an adenosine kinaseRIGEL PHARMACEUTICALS INC·Filed 2006·Application pending·0 cites
- 2466US10858335B22,3-Disubstituted pyridine compounds as TGF-β inhibitors and methods of useRIGEL PHARMACEUTICALS INC·Filed 2019·Granted Dec 8, 2020·0 cites·17 claims
- 2566US7604951B2Method for identifying compounds that modulate RXR associated processes with IgE productionRIGEL PHARMACEUTICALS INC·Filed 2006·Granted Oct 20, 2009·1 cites·11 claims
- 2666US7598050B2Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a chloride intracellular channel 1 proteinRIGEL PHARMACEUTICALS INC·Filed 2006·Granted Oct 6, 2009·1 cites·14 claims
- 2766US2022298213A1In vivo engineered cereblon proteinVIVIDION THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2864US7422867B2Methods of identifying compounds that modulate IL-4 receptor mediated IgE synthesis utilizing a CLLD8 proteinRIGEL PHARMACEUTICALS INC·Filed 2007·Granted Sep 9, 2008·0 cites·11 claims
- 2964US2021276982A1TGF-ß INHIBITORSRIGEL PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 3062US2021380703A1Acvr2a-specific antibody and method of use thereofRIGEL PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 3162US2003170724A1Methods of identifying target polypeptidesFiled 2002·Application pending·0 cites
- 3260US7378251B2Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a thioredoxin-like 32 kDa proteinRIGEL PHARMACEUTICALS INC·Filed 2002·Granted May 27, 2008·2 cites·28 claims
- 3360US7241581B2Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a c-MYC proteinRIGEL PHARMACEUTICALS INC·Filed 2002·Granted Jul 10, 2007·0 cites·20 claims
- 3460US2020339678A1Antigen binding molecules to tigitRIGEL PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 3560US2007135350A1Methods of Identifying Compounds that Modulate IL-4 Receptor-Mediated IgE Synthesis Utilizing a B-Cell Associated ProteinRIGEL PHARMACEUTICALS INC·Filed 2007·Application pending·0 cites
- 3659US11104737B2ACVR2A-specific antibody and method of treatment of muscle atrophyRIGEL PHARMACEUTICALS INC·Filed 2018·Granted Aug 31, 2021·0 cites·17 claims
- 3759US7141434B2Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing an adenosine kinaseRIGEL PHARMACEUTICALS INC·Filed 2002·Granted Nov 28, 2006·0 cites·27 claims
- 3859US2007054862A1Methods of Identifying Compounds that Modulate IL-4 Receptor-Mediated IgE Synthesis Utilizing an Adenosine KinaseRIGEL PHARMACEUTICALS INC·Filed 2006·Application pending·0 cites
- 3958US11352360B2TGF-beta inhibitorsRIGEL PHARMACEUTICALS INC·Filed 2019·Granted Jun 7, 2022·0 cites·21 claims
- 4058US2021002337A1In vivo engineered cereblon proteinVIVIDION THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 4156US7872096B2Methods for cyclizing synthetic polymersRIGEL PHARMACEUTICALS INC·Filed 2005·Granted Jan 18, 2011·0 cites·12 claims
- 4256US2007105140A1In vivo production of cyclic peptidesLORENS JAMES B·Filed 2006·Application pending·0 cites
- 4355US10287295B2TGF-β inhibitorsRIGEL PHARMACEUTICALS INC·Filed 2018·Granted May 14, 2019·0 cites·20 claims
- 4455US9511058B2Methods for using carboxamide, sulfonamide and amine compoundsRIGEL PHARMACEUTICALS INC·Filed 2014·Granted Dec 6, 2016·0 cites·25 claims
- 4555US7208289B2Methods of identifying compounds that modulate IL-4 receptor mediated IgE synthesis utilizing a CLLD8 proteinRIGEL PHARMACEUTICALS INC·Filed 2004·Granted Apr 24, 2007·0 cites·26 claims
- 4655US2008003618A1Methods of identifying compounds that modulate il-4 receptor-mediated ige synthesis utilizing a b-cell associated proteinRIGEL PHARMACEUTICALS INC·Filed 2006·Application pending·0 cites
- 4754US2007244033A1Methods of identifying compounds that modulate il-4 receptor-mediated ige synthesis utilizing a c-myc proteinRIGEL PHARMACEUTICALS INC·Filed 2006·Application pending·0 cites
- 4853US9644224B2Methods for cyclizing synthetic polymersKINSELLA TODD M·Filed 2010·Granted May 9, 2017·0 cites·9 claims
- 4952US7863222B2shRNA libraryRIGEL PHARMACEUTICALS INC·Filed 2008·Granted Jan 4, 2011·0 cites·7 claims
- 5051US2013310340A1Method of treating muscular degradationRIGEL PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
Showing the top 50 of 66 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →